Copyright
©The Author(s) 2017.
World J Gastroenterol. Dec 14, 2017; 23(46): 8120-8127
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8120
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8120
Table 1 Representative direct-acting antivirals, their targets and hepatitis C virus genotypes
Target regions | DAAs | HCV GTs |
NS3/4A | Glecaprevir | Pan-GTs |
Grazoprevir | 1, 4 | |
Asunaprevir | 1b | |
Paritaprevir | 1, 2a, 4 | |
Simeprevir | 1, 4 | |
Telaprevir | 1, 2 | |
Boceprevir | 1 | |
NS5A | Pibrentasvir | Pan-GTs |
Velpatasvir | Pan-GTs | |
Elbasvir | Pan-GTs | |
Daclatasvir | Pan-GTs | |
Ledipasvir | 1, 4, 5 | |
Ombitasvir | 1, 4 | |
NS5B | Sofosbuvir [nucleos(t)ide inhibitor] | Pan-GTs |
Dasabuvir [non-nucleos(t)ide inhibitor] | 1 |
Table 2 Resistance-associated substitutions or treatment-emergent substitutions of hepatitis C virus NS5B nucleos(t)ide inhibitors
Domains of HCV NS5B polymerase[45] | HCV genotypes (GTs) | Ref. | ||
GT1 | GT1a | GT1b | ||
Fingers domain (AA1-188, 226-287) | C14R | [40] | ||
D61G | [40] | |||
T77T/A | [41] | |||
S96T | [42] | |||
N142T | N142S | [40,42] | ||
L159F | [40-44] | |||
E237G | [40] | |||
S282T | S282R | [40-42] | ||
Palm domain (AA188-226, 287-371) | M289I/L | [42,44] | ||
L314P | [40] | |||
C316R | [41] | |||
L320F | L320I/V | [40-42] | ||
V321A | V321I | [40,42,43] | ||
T344I | [40] | |||
Thumb domain (AA371-530) | F415Y | [43] | ||
E440G, E/G | [42] | |||
S470G | [40] |
Table 3 Retreatment regimens for patients with hepatitis C virus infection for whom the initial combination of direct-acting antivirals has failed
Patients | APASL (2016)[1] | AASLD (2017)[28] |
GT1 | ||
Peginterferon and ribavirin plus HCV NS3/4A inhibitors-failure non-cirrhotic patients | Sofosbuvir/ledipasvir 12 wk | Sofosbuvir/ledipasvir 12 wk |
Sofosbuvir/velpatasvir 12 wk | ||
Glecaprevir/pibrentasvir 12 wk | ||
Peginterferon and ribavirin plus HCV NS3/4A inhibitors-failure compensated cirrhotic patients | Sofosbuvir/ledipasvir 12 wk | Sofosbuvir/velpatasvir 12 wk |
Glecaprevir/pibrentasvir 12 wk | ||
(For GT1b) Elbasvir/grazoprevir 12 wk | ||
HCV NS5A inhibitors-failure non-cirrhotic patients | Wait | Sofosbuvir/velpatasvir/voxilaprevir 12 wk |
HCV NS5A inhibitors-failure compensated cirrhotic patients | RAS check | Sofosbuvir/velpatasvir/voxilaprevir 12 wk |
Non-NS5A inhibitor/ sofosbuvir-failure non-cirrhotic patients | N/A | Glecaprevir/pibrentasvir 12 wk |
(For GT1a) | ||
Sofosbuvir/velpatasvir/voxilaprevir 12 wk | ||
(For GT1b) Sofosbuvir/velpatasvir 12 wk | ||
Non-NS5A inhibitor/ sofosbuvir-failure compensated cirrhotic patients | N/A | Glecaprevir/pibrentasvir 12 wk |
(For GT1a) | ||
Sofosbuvir/velpatasvir/voxilaprevir 12 wk | ||
(For GT1b) Sofosbuvir/velpatasvir 12 wk | ||
GT2 | ||
Sofosbuvir/ribavirin-failure patients | N/A | Sofosbuvir/velpatasvir 12 wk |
Glecaprevir/pibrentasvir 12 wk | ||
GT3 | ||
DAA (including NS5A inhibitors) - failure patients | N/A | Sofosbuvir/velpatasvir/voxilaprevir 12 wk |
(For NS5A inhibitor-failure) weight-based ribavirin is recommended | ||
GT4 | ||
DAA (including NS5A inhibitors) - failure patients | N/A | Sofosbuvir/velpatasvir/voxilaprevir 12 wk |
GT5/GT6 | ||
DAA (including NS5A inhibitors) - failure patients | N/A | Sofosbuvir/velpatasvir/voxilaprevir 12 wk |
- Citation: Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127
- URL: https://www.wjgnet.com/1007-9327/full/v23/i46/8120.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i46.8120